← ANALYST RATINGS · TIPRANKS
Protagonist Therapeutics (PTGX): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy0 Hold0 Sell
Ratings of 13 analysts in the last 3 months12-month forecast
Based on 13 price targets given in the last 3 months, the average target is $174, the highest $190, the lowest $149. The average is +35.3% from the last price of $129.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $151 → $147−2.6% | Buy | +14.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $154 → $144−6.5% | Buy | +11.8% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $151 → $142−6.0% | Buy | +10.3% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $141 → $142+0.7% | Buy | +10.3% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $151 → $150−0.7% | Buy | +16.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $141 → $147+4.3% | Buy | +14.2% | Upgrade | 17.10.26on TipRanks 00:06 | — | |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $182 | Buy | +41.4% | Reiterated | 15.10.26on TipRanks 07:50 | −0.1%next day −4.6% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $180 | Buy | +39.8% | Reiterated | 13.10.26on TipRanks 04:50 | −4.4%next day −0.5% | ↗ |
| Unknown Analyst | Leerink Partners | $150 → $190+26.7% | Buy | +47.6% | Assigned | 12.10.26on TipRanks 08:15 | +0.9%next day −4.4% | ↗ |
| Name not given | — | $184 | Buy | +42.9% | Initiated | 12.10.26on TipRanks 05:40 | +0.9%next day −4.4% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | — | Buy | — | Reiterated | 01.09.26on TipRanks 08:05 | −0.2%next day −0.7% · 5 days −1.0% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $167 → $170+1.8% | Buy | +32.0% | Assigned | 01.09.26on TipRanks Aug 31 08:30 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $186 | Buy | +44.5% | Reiterated | 31.08.26on TipRanks Sep 1 09:05 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $149 | Buy | +15.7% | Reiterated | 31.08.26on TipRanks Sep 1 08:30 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $173 | Buy | +34.4% | Reiterated | 31.08.26on TipRanks 20:30 | −0.2%next day −0.7% · 5 days −1.0% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $165 → $170+3.0% | Buy | +32.0% | Reiterated | 31.08.26on TipRanks 14:20 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $173 | Buy | +34.4% | Reiterated | 31.08.26on TipRanks 07:25 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $178 | Buy | +38.3% | Reiterated | 30.08.26on TipRanks Aug 31 08:05 | +2.7%next day −0.2% · 5 days −1.1% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $155 | Buy | +20.4% | Reiterated | 05.08.26on TipRanks Aug 6 06:00 | +1.3%next day +6.6% · 5 days +10.3% | ↗ |
| Unknown Analyst | Jefferies | $121 | Buy | −6.0% | Reiterated | 16.07.26on TipRanks Jul 17 00:05 | −2.0%next day +7.7% · 5 days +4.3% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $82.00 | Buy | −36.3% | Reiterated | 03.11.25on TipRanks Nov 4 10:45 | −3.6%next day +1.9% · 5 days +9.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Protagonist Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $167 at a price of $141 (+18.5%); now: $174 at $129 (+35.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 26 | 14 | 16 | 24 | 27 | 25 |
| Hold | 2 | 2 | 2 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $2.39 (from $0.13 to $3.40). Last quarter: $2.29.
Sales
Next quarter’s sales estimate — $230M (from $82M to $287M). Last quarter: $213M.
Best top-analyst consensus in the sector · Healthcare
About Protagonist Therapeutics
- CEO: Dinesh V. Patel
- Employees: 141
- 7707 Gateway Boulevard, Newark, CA, 94560, US
- www.protagonist-inc.com
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗